Chefaro UK Ltd

4th Floor, Hamilton House, Mabledon Place, Bloomsbury, London, WC1H 9BB, UK
Telephone: +44 (0)207 554 8791
Medical Information e-mail: enquiries@chefaro.co.uk
Customer Care direct line: +44 (0)1748 828 860


Summary of Product Characteristics last updated on the eMC: 24/02/2011
SPC Drapolene Cream


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Drapolene Cream


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Drapolene contains:

Benzalkonium chloride solution 0.02% w/w

Equivalent to benzalkonium chloride 0.01% w/w

Cetrimide 0.2% w/w


Go to top of the page
3. PHARMACEUTICAL FORM

Cream for topical application.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

Drapolene is indicated for the relief of nappy rash and for use as an adjunct to baby care hygiene for the prevention of nappy rash.

Drapolene is indicated for the relief of urinary dermatitis in adults, and as an adjunct to patient care hygiene for the prevention of urinary dermatitis.

Drapolene is indicated for the symptomatic relief of minor burns, limited sunburn and the effects of weather.


Go to top of the page
4.2 Posology and method of administration

Route of administration:

Topical

Dosage:

Babies: The nappy area should be washed then dried thoroughly at each change of nappy. Drapolene Cream should be applied, paying particular attention to folds in the skin.

Adults: The affected area (or the area of application) should be washed and dried thoroughly before applying Drapolene. Regular routine application is advised.

Drapolene should be applied as required for minor burns, limited sunburn and the effects of weather.

Use in the Elderly

No special comment


Go to top of the page
4.3 Contraindications

It is inadvisable to apply Drapolene Cream to a baby or adult who has an established hypersensitivity to benzalkonium chloride, cetrimide or lanolin. Use should be discontinued if an allergic hypersensitivity reaction is suspected.


Go to top of the page
4.4 Special warnings and precautions for use

The packs carry the following additional warnings:

Store below 25°C

For external use only

Keep out of the reach of children


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None known.


Go to top of the page
4.6 Pregnancy and lactation

When used in accordance with the specified indications, systemic absorption of the specified components is not envisaged and so there are no special precautions/warnings appropriate to pregnancy and lactation.


Go to top of the page
4.7 Effects on ability to drive and use machines

None.


Go to top of the page
4.8 Undesirable effects

Allergic hypersensitivity reactions may occur in individuals who are sensitive to one or several components of Drapolene Cream.

Hypersensitivity to lanolin is recognised but is rare.

In a few individuals, benzalkonium chloride, used as a preservative in ophthalmic solutions, was associated with oedema and conjunctivitis. Dermatitis as a result of contact allergy to benzalkonium chloride in plaster of Paris has also been reported.

Hypersensitivity to cetrimide is also known to occur, presenting as a localised contact dermatitis. In severe cases the rash may be generalised.


Go to top of the page
4.9 Overdose

There are no reports of adverse events resulting from excessive application or accidental ingestion of Drapolene Cream.

In cases of accidental ingestion, symptomatic treatment is appropriate.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Benzalkonium chloride and cetrimide are both quaternary ammonium disinfectants with properties typical of cationic surfactants. This preparation is useful in the treatment of and prevention of nappy rash, acting to suppress the development of ammonia producing organisms usually associated with this condition.


Go to top of the page
5.2 Pharmacokinetic properties

No data is available on the pharmacokinetics of the active ingredients of Drapolene Cream, when used for the specified indications. Systemic absorption of the active ingredients is not envisaged.


Go to top of the page
5.3 Preclinical safety data

None stated.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

White soft paraffin

Wool fat (purified lanolin)

Cetyl alcohol

Polawax

Chlorocresol

Amaranth

Purified water


Go to top of the page
6.2 Incompatibilities

None known.


Go to top of the page
6.3 Shelf life

Tube - 36 months unopened.

Other packs - 36 months unopened.


Go to top of the page
6.4 Special precautions for storage

Store below 25° C.


Go to top of the page
6.5 Nature and contents of container

25, 75, 150, 200 or 300 g - white pigmented polypropylene containers with white-pigmented LDPE snap-fit caps or white-pigmented polypropylene containers with white pigmented LDPE/HDPE snap-fit caps.

500 g polypropylene pots with PVDC faced wad and polypropylene screw caps.

100 g polyolefin/foil/polyolefin laminate tubes with polypropylene caps.


Go to top of the page
6.6 Special precautions for disposal and other handling

None applicable.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Chefaro UK Ltd.

4th Floor,Hamilton House

Mabledon Place,Bloomsbury

LONDON,WC1H 9BB

United Kingdom


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 02855/0016


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

17th January 2005


Go to top of the page
10. DATE OF REVISION OF THE TEXT

14th November 2010



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/7158/SPC/


Active Ingredients/Generics

 
   cetrimide
   benzalkonium chloride